IDEC/GENENTECH RITUXAN NON-HODGKIN'S LYMPHOMA RESPONDERS: HALF IN REMISSION AT ONE YEAR; FIRST-LINE AND COMBINATION CHEMOTHERAPY STUDIES WITH MAB PLANNED
Executive Summary
Half of the responders to Idec/Genentech's Rituxan for non-Hodgkin's lymphoma remain in remission, Idec said July 25 following a favorable review by FDA's Biological Response Modifiers Advisory Committee. Of 80 responders in the Rituxan pivotal trial, 38 are still in remission 11.8 months following treatment.